Daiichi Sankyo submits Enhertu sNDA to Japan’s MHLF for patients with HER2 low or HER2 ultralow metastatic breast cancer: Tokyo Saturday, October 5, 2024, 10:00 Hrs [IST] Daiich ...

We're going to check out a few of the best picks from our screener tool. Overview: Daiichi Sankyo Company, Limited is a ...

Oncolytics stock soars as the company seeks an accelerated approval pathway for its lead candidate, pelareorep, to treat a ...

AstraZeneca and Daiichi Sankyo's supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan) has ...

The market for B7-H3 inhibitors is expected to grow significantly in the coming years. This is due to the rising investment from leading pharma companies such as GSK, Merck, and others, the increasing ...

The trial was conducted across Germany, with patients' LDL-C levels measured at pretreatment, year one, and year two.

The European Commission (EC) has granted approval for Daiichi Sankyo’s Vanflyta (quizartinib) for newly diagnosed fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) positive acute ...

The antibody-drug conjugate will be reviewed for the potential treatment of previously treated, unresectable or metastatic ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...